Literature DB >> 6861815

Experience with piroxicam in general practice: results of a German multicenter study on 18,888 patients.

N Langloh.   

Abstract

18,888 patients with chronic or extra-articular rheumatic diseases were treated for an average period of 36.1 or 26.9 days with the new non-steroidal anti-rheumatic agent piroxicam. In particular, piroxicam had a positive effect in terms of providing relief from pain. Side effects were relatively rare and seldom required discontinuation of treatment. In about 75% of the patients the maintenance dose was 20 mg piroxicam in a single daily dose. No influence on the laboratory values or accompanying diseases were observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861815

Source DB:  PubMed          Journal:  Eur J Rheumatol Inflamm        ISSN: 0140-1610


  3 in total

1.  Single-dose and steady-state pharmacokinetics of piroxicam in elderly vs young adults.

Authors:  A Darragh; A J Gordon; H O'Byrne; D Hobbs; E Casey
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 2.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

3.  A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis.

Authors:  G Husby; I Holme; H E Rugstad; O B Herland; K E Giercksky
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.